Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
2.860
-0.080 (-2.72%)
Dec 3, 2024, 12:08 PM EST - Market open
Galmed Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for GLMD.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for GLMD.
Recommendation Trends
Rating | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $48 | Hold → Strong Buy | Upgrades | $48 | +1,578.26% | Jul 24, 2023 |
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 8, 2022 |
Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $900 → $180 | Strong Buy → Hold | Downgrades | $900 → $180 | +6,193.49% | Aug 8, 2022 |
Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 18, 2022 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 3, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.32
from -30.00
EPS Next Year
-1.05
from -1.32
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | |||
Avg | n/a | n/a | n/a | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | -1.35 | -1.08 | -1.06 | |
Avg | -1.32 | -1.05 | -1.03 | |
Low | -1.26 | -1.01 | -0.99 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | - | - | - | |
Avg | - | - | - | |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.